Show simple item record

dc.contributor.authorVan Dyck, Walter
dc.contributor.authorSchoonaert, Lies
dc.contributor.authorGeldof, Tine
dc.contributor.authorGovaerts, Laurenz
dc.date.accessioned2019-03-10T22:22:07Z
dc.date.available2019-03-10T22:22:07Z
dc.date.issued2018
dc.description.abstractTo balance the societal need for affordability of medicines with the industrial need for sustained innovation, the present pharmaceutical technology supply-driven system needs to become a societal demand-driven system. Value-based pricing is considered to be a key component of such a system, next to the conditional dialogue between payer and industry we proposed in previous work (Van Dyck, De Grève et al. 2016) in which it should be embedded. To find out how far Belgian pharmaceutical healthcare-related decision-making has evolved within this paradigm, we empirically investigated the access and reimbursement decision-making of the Belgian Commission for Reimbursement of Medicines (CRM) for the period 2010 – 2017. We combined this investigation with previous work in a meta-analysis in order to have the most complete picture possible of the present factors influencing decision-making in the Belgian system.en_US
dc.language.isoenen_US
dc.relation.ispartofseriesVlerick Policy Paper Series/8en_US
dc.subjectHealthcareen_US
dc.titleAccess decision-making in the Belgian Commission for reimbursement of medicines 2010-2017: Investigating the readiness for value-based pricingen_US
dc.source.numberofpages47en_US
vlerick.knowledgedomainSpecial Industries : Healthcare Managementen_US
vlerick.typecommPolicy paper
vlerick.vlerickdepartmentTOMen_US
vlerick.vlerickdepartmentTOM
dc.identifier.vperid31183
dc.identifier.vperid211254
dc.identifier.vperid176581
dc.identifier.vperid219312


This item appears in the following Collection(s)

Show simple item record